Comparative Assessment of FSH, LH, Testosterone, Prolactin, and Body Mass Index in Women with Polycystic Ovary Syndrome: A Case-Control Study
DOI:
https://doi.org/10.64943/ljmas.2026.040403Keywords:
Polycystic ovary syndrome, PCOS, FSH, LH, LH/FSH ratio, Testosterone, Prolactin, Body mass indexAbstract
Background: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age and is characterized by hormonal and metabolic disturbances. Objective: This study aimed to compare reproductive hormone levels, the LH/FSH ratio, and body mass index (BMI) between women with PCOS and healthy controls, and to evaluate the correlation between BMI and hormonal parameters in women with PCOS. Methods: A case-control study was conducted involving 80 women, including 40 women diagnosed with PCOS and 40 healthy controls. Serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, and prolactin were measured using standard laboratory methods. BMI was calculated for all participants. Statistical analyses included the independent samples t-test and Pearson's correlation analysis, with statistical significance set at P < 0.05. Results: Women with PCOS had significantly lower FSH levels and significantly higher BMI, testosterone, prolactin, and LH/FSH ratio than healthy controls (P < 0.05). Although LH levels were higher in the PCOS group, the difference was not statistically significant (P = 0.086). Pearson's correlation analysis revealed no significant associations between BMI and the measured hormonal parameters in women with PCOS. Conclusion: Women with PCOS exhibit significant endocrine and metabolic alterations compared with healthy controls. Assessment of reproductive hormones, LH/FSH ratio, and BMI may improve the clinical evaluation of PCOS. However, BMI was not significantly correlated with hormonal parameters in the studied population.
References
1. Bai, H., Ding, H., & Wang, M. (2024). Polycystic ovary syndrome (PCOS): symptoms, causes, and treatment. Clinical and Experimental Obstetrics & Gynecology, 51(5), 126.
2. Zehravi, M., Maqbool, M., & Ara, I. (2021). Polycystic ovary syndrome and reproductive health of women: a curious association. International journal of adolescent medicine and health, 33(6), 333-337.
3. Stener-Victorin, E., Teede, H., Norman, R. J., Legro, R., Goodarzi, M. O., Dokras, A., ... & Piltonen, T. T. (2024). Polycystic ovary syndrome. Nature reviews Disease primers, 10(1), 27. https://doi.org/10.1038/s41572-024-00511-3
4. 4.Su, P., Chen, C. & Sun, Y. Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation. J Ovarian Res 18, 34 (2025). https://doi.org/10.1186/s13048-025-01621-6
5. Harada, M. (2022). Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. Reproductive medicine and biology, 21(1), e12487. https://doi:10.1002/rmb2.12487
6. Lonardo, M. S., Cacciapuoti, N., Guida, B., Di Lorenzo, M., Chiurazzi, M., Damiano, S., & Menale, C. (2024). Hypothalamic-ovarian axis and adiposity relationship in polycystic ovary syndrome: physiopathology and therapeutic options for the management of metabolic and inflammatory aspects. Current Obesity Reports, 13(1), 51-70. https://doi.org/10.1007/s13679-023-00531-2
7. Abdul-Sahib, R. J., & Faraj, S. H. (2023). MOLECULAR ANALYSIS OF CYP17 GENE PROMOTER IN IRAQI INFERTILE WOMEN. Ann. For. Res, 66(1), 2518-2525.
8. Afsana, F. (2025). Role of Hyperandrogenism in PCOS Pathogenesis. In Current and Emerging Concepts of Polycystic Ovary Syndrome Manual from MP PCOS Society (Part 1) (pp. 101-108). Bentham Science Publishers. https://doi.org/10.2174/97988988109311250101
9. Unluhizarci, K., Karaca, Z., & Kelestimur, F. (2021). Role of insulin and insulin resistance in androgen excess disorders. World journal of diabetes, 12(5), 616. https://doi.org/10.4239/wjd.v12.i5.616
10. Mastnak, L., Herman, R., Ferjan, S., Janež, A., & Jensterle, M. (2023). Prolactin in polycystic ovary syndrome: metabolic effects and therapeutic prospects. Life, 13(11), 2124.https://doi.org/10.3390/life13112124
11. Lim, S. S., Kakoly, N. S., Tan, J. W. J., Fitzgerald, G., Bahri Khomami, M., Joham, A. E., ... & Moran, L. J. (2019). Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta analysis and metaregression. Obesity reviews, 20(2), 339-352. https://doi.org/10.1111/obr.12762
12. Barber, T. M., & Franks, S. (2021). Obesity and polycystic ovary . Clin Endocrinol (Oxf). 2021; 95: 531–541.https://doi.org/10.1111/cen.14421
13. Heymsfield, S. B., Sorkin, J. D., Thomas, D. M., Yang, S., Heo, M., McCarthy, C., ... & Pietrobelli, A. (2025). Weight/height2: Mathematical overview of the world's most widely used adiposity index. Obesity Reviews, 26(1), e13842.doi:10.1111/obr.13842
14. Alhassan, S., Elmugadam, A., Elfadil, G. A., Abubaker, N., Elfaki, E. M., Hamza, A., ... & Karar, T. (2023). Diagnostic performance of anti-Müllerian hormone, luteinizing hormone to follicle-stimulating hormone ratio, testosterone, and prolactin to predict polycystic ovary syndrome among Sudanese women. International Journal of Women's Health, 837-843.https://doi.org/10.2147/IJWH.S403347
15. Yang, J., & Chen, C. (2024). Hormonal changes in PCOS. Journal of Endocrinology, 261(1).https://doi.org/10.1530/JOE-23-0342
16. Mahmud, A. A., Anu, U. H., Foysal, K. A., Hasan, M., Sazib, S. M., Ragib, A. A., ... & Emran, T. B. (2022). Elevated serum malondialdehyde (MDA), insulin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and thyroid-stimulating hormone (TSH), and reduced antioxidant vitamins in polycystic ovarian syndrome patients. Narra J, 2(1), e56. https://doi.org/10.52225/narra.v2i1.56
17. Najdgholami, Z., Sedgi, F. M., Ghalishourani, S. S., Feyzpour, M., & Rahimlou, M. (2025). Flaxseed intervention and reproductive endocrine profiles in patients with polycystic ovary syndrome: an open-labeled randomized controlled clinical trial. Frontiers in endocrinology, 16, 1531762. https://doi: 10.3389/fendo.2025.1531762
18. Xu, J., Chen, W. H., Huang, M. N., Zheng, L. T., Huang, S. Y., Lin, S., & Shi, Q. R. (2025). Recent advances in reprogramming lactate metabolism in polycystic ovary syndrome. Journal of Ovarian Research, 18(1), 221. https://doi.org/10.1186/s13048-025-01797-x
19. McCartney, C. R., Campbell, R. E., Marshall, J. C., & Moenter, S. M. (2022). The role of gonadotropin‐releasing hormone neurons in polycystic ovary syndrome. Journal of neuroendocrinology, 34(5), e13093. doi:10.1111/jne.13093
20. Abdul-Sahib, R. J., & Faraj, S. H. (2026). Association of FSHβ gene (−211 G>T) polymorphism with infertility in Iraqi women in Maysan Governorate. Libyan Journal of Ecological & Environmental Sciences and Technology, 8(2), 22–27. https://doi.org/10.63359/d8bcyj16
21. Ruddenklau, A., & Campbell, R. E. (2019). Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology, 160(10), 2230-2242. https://doi.org/10.1210/en.2019-00428
22. Ding, H., Zhang, J., Zhang, F., Zhang, S., Chen, X., Liang, W., & Xie, Q. (2021). Resistance to the insulin and elevated level of androgen: a major cause of polycystic ovary syndrome. Frontiers in endocrinology, 12, 741764.. https://doi.org/10.3389/fendo.2021.741764
23. Wang, K., Li, Y., & Chen, Y. (2023). Androgen excess: a hallmark of polycystic ovary syndrome. Frontiers in endocrinology, 14, 1273542. https://doi.org/10.3389/fendo.2023.1273542
24. Athar, F., Karmani, M., & Templeman, N. M. (2024). Metabolic hormones are integral regulators of female reproductive health and function. Bioscience reports, 44(1), BSR20231916. https://doi.org/10.1042/BSR20231916
25. Chen, X., Wan, Y., & Xie, L. (2025). Insulin resistance in polycystic ovary syndrome: pathophysiological mechanisms of menstrual dysfunction and evidence-based treatment strategies. Biology of Reproduction, 113(6), 1340-1354. https://doi.org/10.1093/biolre/ioaf197
26. Rambaran, N., & Islam, M. S. (2025). Decoding androgen excess in polycystic ovary syndrome: Roles of insulin resistance and other key intraovarian and systemic factors. World journal of diabetes, 16(7), 108789. https://doi.org/10.4239/wjd.v16.i7.108789
27. Szybiak-Skora, W., Cyna, W., & Lacka, K. (2025). New insights in the diagnostic potential of sex hormone-binding globulin (SHBG)—clinical approach. Biomedicines, 13(5), 1207.https://doi.org/10.3390/biomedicines13051207
28. Jabbar, R. (2026). Association Between Age, Body Mass Index, and Hypertension Among Adults in Maysan Governorate, Iraq: A Cross-Sectional Study. Libyan Journal of Applied and Contemporary Sciences, 50–58. https://doi.org/10.64943/ljacs.2026.010205.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 raghad jabbar Abdul Sahib

This work is licensed under a Creative Commons Attribution 4.0 International License.